Volatility continues to dog CAR T stocks

After a partial recovery last Friday, shares of companies developing chimeric antigen receptor (CAR) T cell therapies fell on Tuesday after an article in the New York Times suggested the sector may be overheated. The article noted "the technique is still early in development and can cause severe side effects."

Kite Pharma Inc. (NASDAQ:KITE) told BioCentury it fielded questions from generalist investors in response to the article. The company's shares fell $8.50 (10%) to $74.16 on Tuesday. ...